PMID: 26902041Feb 24, 2016Paper

Head-To-Head Comparison of Two Years Efficacy of Entecavir and Tenofovir in Patients with Treatment-Naïve Chronic Hepatitis B--The Real Life Data

Hepato-gastroenterology

Abstract

Entecavir and tenofovir are generally accepted as first-line therapeutic options in chronic hepatitis B. Both of them are potent and have high genetic barrier to viral resistance. Aim of this study was to compare the two-year efficacy of entecavir and tenofovir in treatment-naive chronic hepatitis B patients. Study was comprised 164 patients with treatment naïve chronic hepatitis or compensated liver cirrhosis. At least twenty four mouths of entecavir or tenofovir were given to all patients. Mean ALT levels, ALT normalization rates, mean HBV DNA levels, HBV DNA negativity rates and HBeAg negativity rates were not different in entecavir and tenofovir groups throughout the study. Mean serum creatinine levels were also similar between groups. Two-years of antiviral treatment of treatment-naïve patients with chronic hepatitis B or cirrhosis with entecavir or tenofovir were equally effective.

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Seyfettin KöklüOzlem Baykal
Nihon rinsho. Japanese journal of clinical medicine
Fumio ImazekiOsamu Yokosuka
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Jun-qian LiXue-zhang Duan
© 2022 Meta ULC. All rights reserved